Evidence map›Paper›PMID 22174129›Full record

ArticleScience (New York, N.Y.)2012

Asymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibility.

Bree B Aldridge, Marta Fernandez-Suarez, Danielle Heller, Vijay Ambravaneswaran, Daniel Irimia, Mehmet Toner, Sarah M Fortune

Abstract read
In one paragraph

Article in Science (New York, N.Y.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 266 papers.

0numbers the graph read from it
0cells of the map it votes in
266citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

266 citing papers in PubMed.

  1. MakingCell insight · 2026
    Review
  2. The polar landscape of bacterial pathogens and predators.Current opinion in microbiology · 2026
    Review
  3. Structure, assembly, and mechanism of the MmpL family of transporters.Microbiology and molecular biology reviews : MMBR · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. A new Persister Enrichment Model inbioRxiv : the preprint server for biology · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

206 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Bree B AldridgeDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA.
Marta Fernandez-Suarez
Danielle Heller
Vijay Ambravaneswaran
Daniel Irimia
Mehmet Toner
Sarah M Fortune

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Daniel Lingwood · 2004 to 2026
$94.4M
Bio-MicroElectroMechanical Systems Resource CenterP41EB002503 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI TONER, MEHMET · 2004 to 2018
$17.4M
Variation in M. tuberculosis in response to host selectionDP2OD001378 · OD · HARVARD SCHOOL OF PUBLIC HEALTH · PI FORTUNE, SARAH · 2007 to 2009
$2.5M
NCCDPHP CDC HHS 1DP20D001378NIAID NIH HHS P30 AI060354NIBIB NIH HHS P41 EB002503NIH HHS DP2 OD001378
6 · The paper itself

Abstract

Cells use both deterministic and stochastic mechanisms to generate cell-to-cell heterogeneity, which enables the population to better withstand environmental stress. Here we show that, within a clonal population of mycobacteria, there is deterministic heterogeneity in elongation rate that arises because mycobacteria grow in an unusual, unipolar fashion. Division of the asymmetrically growing mother cell gives rise to daughter cells that differ in elongation rate and size. Because the mycobacterial cell division cycle is governed by time, not cell size, rapidly elongating cells do not divide more frequently than slowly elongating cells. The physiologically distinct subpopulations of cells that arise through asymmetric growth and division are differentially susceptible to clinically important classes of antibiotics.

Indexed as

Anti-Bacterial AgentsCell CycleCell DivisionCell WallCycloserineEscherichia coliIsoniazidMeropenemMicrobial Sensitivity TestsMicrofluidic Analytical TechniquesMycobacterium smegmatisMycobacterium tuberculosisRifampinThienamycinsTime FactorsAnti-Bacterial AgentsCycloserineIsoniazidMeropenemRifampinThienamycins

Identifiers

PMID22174129
PMCPMC3397429

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.